Effect of different dosing regimens of exon skipping antisense oligonucleotides on functional outcome in the mdx mouse model of Duchenne muscular dystrophy

被引：0
|
作者：
Datson, N. [1 ]
Weij, R. [1 ]
Bijl, S. [1 ]
Janson, A. [1 ]
Vermue, R. [1 ]
Testerink, J. [1 ]
van Deutekom, J. [1 ]
机构：
[1] BioMarin, Leiden, Netherlands
来源：
NEUROMUSCULAR DISORDERS | 2015年 / 25卷
关键词：
D O I：
10.1016/j.nmd.2015.06.375
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
G.P.351
引用
收藏
页码：S291 / S291
页数：1
相关论文
共 50 条
  • [31] Spermatogenesis in Mdx Mouse Model of Duchenne Muscular Dystrophy
    Braz, Anine F.
    Gomes, Vilessa A.
    Siman, Veronica A.
    Matta, Sergio L. P.
    Clebis, Naianne K.
    Oliveira, Moacir F.
    Morais, Danielle B.
    Moura, Carlos Eduardo B.
    ANALYTICAL AND QUANTITATIVE CYTOPATHOLOGY AND HISTOPATHOLOGY, 2018, 40 (03): : 125 - 131
  • [32] The mdx mouse model as a surrogate for Duchenne muscular dystrophy
    Partridge, Terence A.
    FEBS JOURNAL, 2013, 280 (17) : 4177 - 4186
  • [33] Exon skipping therapy for Duchenne muscular dystrophy - it takes more than an antisense oligonucleotide
    Aartsma-Rus, Annemieke
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2018, 256
  • [34] Towards clinical studies on antisense-mediated exon skipping in Duchenne Muscular Dystrophy
    van Ommen, Gert-Jan B.
    Heemskerk, Hans
    Aartsma-Rus, Annemieke
    de Winter, Christa
    van Kuik, Petra
    de Kimpe, Sjef
    Platenburg, Gerard
    van Deutekom, Judith C. T.
    NEUROMUSCULAR DISORDERS, 2006, 16 : S95 - S95
  • [35] Antisense Oligonucleotide-Mediated Exon Skipping for Duchenne Muscular Dystrophy: Progress and Challenges
    Arechavala-Gomeza, Virginia
    Anthony, Karen
    Morgan, Jennifer
    Muntoni, Francesco
    CURRENT GENE THERAPY, 2012, 12 (03) : 152 - 160
  • [36] New Approach for Antisense Oligonucleotide-Mediated Exon Skipping in Duchenne Muscular Dystrophy
    Aoki, Yoshitsugu
    Nagata, Tetsuya
    Takeda, Shin'ichi
    JOURNAL OF ADVANCED COMPUTATIONAL INTELLIGENCE AND INTELLIGENT INFORMATICS, 2012, 16 (04) : 521 - 526
  • [37] Theoretic Applicability of Antisense-Mediated Exon Skipping for Duchenne Muscular Dystrophy Mutations
    Aartsma-Rus, Annemieke
    Fokkema, Ivo
    Verschuuren, Jan
    Ginjaar, Leke
    van Deutekom, Judith
    van Ommen, Gert-Jan
    den Dunnen, Johan T.
    HUMAN MUTATION, 2009, 30 (03) : 293 - 299
  • [38] ANTISENSE-BASED EXON SKIPPING AS A THERAPY FOR DUCHENNE MUSCULAR DYSTROPHY, STATUS AND PROSPECTS
    van Ommen, G. -J.
    Aartsma-Rus, A.
    Evers, M.
    van Roon, W.
    'tHoen, P. -B.
    Kemaladewi, D.
    Verbeek, S.
    Yllmaz-Elis, S.
    Dauwerse, H.
    Lesnik-Oberstein, S.
    den Dunnen, J. T.
    Goemans, N.
    Tulinus, M.
    Verschuuren, J.
    de Kimpe, S.
    Campion, G.
    van Deutekom, J.
    EUROPEAN JOURNAL OF NEUROLOGY, 2011, 18 : 7 - 7
  • [39] Antisense-mediated exon skipping as a gene correction therapy for Duchenne muscular dystrophy
    van Deutekom, J
    Aartsma-Rus, A
    Bremmer-Bout, M
    Janson, A
    den Dunnen, J
    van Ommen, GJ
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2002, 199 : S75 - S76
  • [40] Comparative analysis of antisense oligonucleotide analogs for targeted exon skipping in Duchenne muscular dystrophy
    Aartsma-Rus, A
    Hoen, PAC
    Kaman, WE
    Bremmer-Bout, M
    Janson, AM
    den Dunnen, JT
    van Ommen, GJB
    van Deutekom, JCT
    NEUROMUSCULAR DISORDERS, 2004, 14 (8-9) : 613 - 613
12345